RPL36AP41

Across TCGA pan-cancer cohorts, RPL36AP41 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated RPL36AP41 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RPL36AP41 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL36AP41 expression acts as an unfavorable survival marker, although some lineages such as DLBC and PAAD show a favorable association.

LIHC, DLBC, and MESO are the cancer types where RPL36AP41 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	III,IV	0.214	0.410	.002	51	view →
DLBC	DFS	Tertile	All	1.000	0.648	.005	35	view →
MESO	OS	Tertile	III,IV	0.259	0.640	.014	26	view →
THYM	OS	Quartile	All	0.808	1.000	.006	22	view →
PAAD	OS	Tertile	All	0.743	0.394	.007	22	view →
OV	OS	Tertile	All	0.649	0.743	.033	20	view →
PCPG	DFS	Median	All	0.819	0.983	.001	18	view →
ESCA	DFS	Median	All	0.447	0.927	.003	18	view →
KIRC	OS	Quartile	II,III,IV	0.600	0.736	.019	14	view →
LGG	OS	Quartile	All	0.713	0.825	.022	9	view →
ACC	OS	Median	IV	0.777	0.308	.026	7	view →
STAD	OS	Tertile	IV	0.562	0.185	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

RPL36AP41–LIHC (DFS)

Open the LIHC breakdown →